Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
02.04. | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
25.02. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
31.12.24 | Galera Therapeutics completes acquisition of Nova Pharmaceuticals | 428 | GlobeNewswire (Europe) | Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase... ► Artikel lesen | |
04.09.24 | Delisting of Securities of Liberty Resources Acquisition Corp.; Achari Ventures Holdings Corp. I; PetVivo Holdings, Inc.; Galera Therapeutics, Inc.; Clean Energy Special Situations Corp.; Capitalworks Emerging Markets Acquisition ... | 169 | GlobeNewswire (Europe) | NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of Liberty Resources Acquisition Corp. Liberty Resources... ► Artikel lesen | |
14.08.24 | Galera Therapeutics: Galera Announces Board Approval of Complete Liquidation and Dissolution | 218 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,204 | +0,92 % | Übernahmefantasie angeheizt: Evotec: Neue Hoffnung in der Nierenforschung befeuert Kurs | © Foto: Christian Charisius - dpaDas Hamburger Biotech-Schmiede beteiligt sich an einer großangelegten Studie zu Nierenversagen. Das könnte Evotec völlig neue Marktchancen bescheren.Evotec hat eine... ► Artikel lesen | |
CRISPR THERAPEUTICS | 41,800 | +2,96 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 7,620 | -4,03 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA39261L2049 Green Battery Minerals Inc. 23.06.2025 CA3194101067 First Canadian Grahite Inc. 24.06.2025 Tausch 1:1US15117F8077 Cellectar... ► Artikel lesen | |
GALAPAGOS NV | 24,020 | +0,42 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen | |
CENTOGENE | 0,130 | -12,75 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
NOVOCURE | 15,585 | +1,30 % | Novocure to Report Second Quarter 2025 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 2,813 | -100,00 % | XFRA FA20,0RA0,4070: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFORWARD AIR CORP.... ► Artikel lesen | |
AC IMMUNE | 1,712 | -1,04 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 1,924 | -0,10 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
CYTOKINETICS | 28,400 | 0,00 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of... ► Artikel lesen | |
SPERO THERAPEUTICS | 2,475 | -1,79 % | Alleviating the Pain of CRPS Gave Heather Her Life Back: The Spero Clinic's Role in the Recovery | Is it possible that a simple sound can hurt you? That the sound of a bird singing in the yard can make you scream out in pain? That's the reality of having CRPS. Here's how the Spero Clinic helped Heather... ► Artikel lesen | |
EIGER BIOPHARMACEUTICALS | 5,840 | -100,00 % | China Market Update: US-China Trade Negotiators Climb Switzerland's Face Of The Eiger, Week In Review | ||
VANDA PHARMACEUTICALS | 4,140 | +0,98 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | WASHINGTON, June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial... ► Artikel lesen |